Cargando…
HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment
North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766348/ https://www.ncbi.nlm.nih.gov/pubmed/17176481 http://dx.doi.org/10.1186/1477-7517-3-36 |
_version_ | 1782131658200186880 |
---|---|
author | Tyndall, Mark W Wood, Evan Zhang, Ruth Lai, Calvin Montaner, Julio SG Kerr, Thomas |
author_facet | Tyndall, Mark W Wood, Evan Zhang, Ruth Lai, Calvin Montaner, Julio SG Kerr, Thomas |
author_sort | Tyndall, Mark W |
collection | PubMed |
description | North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes among the city's injection drug users. Between December 2003 and April 2005, a representative sample of 1,035 SIF participants were enrolled in a prospective cohort that required completing an interviewer-administered questionnaire and providing a blood sample for HIV testing. HIV infection was detected in 170/1007 (17%) participants and was associated with Aboriginal ethnicity (adjusted Odds Ratio [aOR], 2.70, 95% Confidence Interval [95% CI], 1.84–3.97), a history of borrowing used needles/syringes (aOR, 2.0, 95% CI, 1.37–2.93), previous incarceration (aOR, 1.87, 95% CI, 1.11–3.14), and daily injection cocaine use (aOR, 1.42, 95% CI, 1.00–2.03). The SIF has attracted a large number of marginalized injection drug users and presents an excellent opportunity to enhance HIV prevention through education, the provision of sterile injecting equipment, and a supervised environment to self-inject. In addition, the SIF is an important point of contact for HIV positive individuals who may not be participating in HIV care and treatment. |
format | Text |
id | pubmed-1766348 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-17663482007-01-11 HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment Tyndall, Mark W Wood, Evan Zhang, Ruth Lai, Calvin Montaner, Julio SG Kerr, Thomas Harm Reduct J Research North America's first government sanctioned medically supervised injection facility (SIF) was opened during September 2003 in Vancouver, Canada. This was in response to a large open public drug scene, high rates of HIV and hepatitis C transmission, fatal drug overdoses, and poor health outcomes among the city's injection drug users. Between December 2003 and April 2005, a representative sample of 1,035 SIF participants were enrolled in a prospective cohort that required completing an interviewer-administered questionnaire and providing a blood sample for HIV testing. HIV infection was detected in 170/1007 (17%) participants and was associated with Aboriginal ethnicity (adjusted Odds Ratio [aOR], 2.70, 95% Confidence Interval [95% CI], 1.84–3.97), a history of borrowing used needles/syringes (aOR, 2.0, 95% CI, 1.37–2.93), previous incarceration (aOR, 1.87, 95% CI, 1.11–3.14), and daily injection cocaine use (aOR, 1.42, 95% CI, 1.00–2.03). The SIF has attracted a large number of marginalized injection drug users and presents an excellent opportunity to enhance HIV prevention through education, the provision of sterile injecting equipment, and a supervised environment to self-inject. In addition, the SIF is an important point of contact for HIV positive individuals who may not be participating in HIV care and treatment. BioMed Central 2006-12-18 /pmc/articles/PMC1766348/ /pubmed/17176481 http://dx.doi.org/10.1186/1477-7517-3-36 Text en Copyright © 2006 Tyndall et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Tyndall, Mark W Wood, Evan Zhang, Ruth Lai, Calvin Montaner, Julio SG Kerr, Thomas HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title | HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title_full | HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title_fullStr | HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title_full_unstemmed | HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title_short | HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment |
title_sort | hiv seroprevalence among participants at a supervised injection facility in vancouver, canada: implications for prevention, care and treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766348/ https://www.ncbi.nlm.nih.gov/pubmed/17176481 http://dx.doi.org/10.1186/1477-7517-3-36 |
work_keys_str_mv | AT tyndallmarkw hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment AT woodevan hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment AT zhangruth hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment AT laicalvin hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment AT montanerjuliosg hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment AT kerrthomas hivseroprevalenceamongparticipantsatasupervisedinjectionfacilityinvancouvercanadaimplicationsforpreventioncareandtreatment |